Summary
Patients with follicular non-Hodgkin's lymphoma (NHL) respond well to chemotherapy but frequently relapse and progress with conversion to more aggressive histology lymphomas. In a prior Cancer and Leukemia Group B (CALGB) trial, oral cyclophosphamide, given as a single agent, was found to be equivalent to a five-drug regimen in remission induction in patients with follicular NHL who had not received prior chemotherapy. Recently, interferon alfa-2b (Intron A; Schering Plough) has been demonstrated to elicit complete or partial responses in up to 50% of patients with nodular NHL who had received prior chemotherapy. In the current CALGB pilot trial, oral cyclophosphamide (100 mg/m2 daily) combined with interferon alfa-2b (2 × 106 IU/m2 s.c. on alternate days) is being evaluated, both in previously treated and untreated patients with stage III or IV follicular NHL, for toxicity, safety and efficacy in remission induction. A total of 68 patients have been entered into this study. Four patients are ineligible on pathology review, and 60 have on-study data currently available. Forty-one (60%) had not received prior chemotherapy and 19 (32%) had previously received some form of chemotherapy. Leukopenia was found to be the single, most common toxicity experienced by all patients. Previously untreated patients experienced leukopenia of <2,000 WBC/μl at a significantly higher rate (53% versus 14%) than a similar patient population receiving oral cyclophosphamide as a single agent in the prior CALGB trial.
Leukopenia was found to be promptly reversible, however, by dose suspension or adjustment, and other toxicities were demonstrated to be mild and tolerable. In patients who had received prior chemotherapy, severe or life-threatening leukopenia (63%), thrombocytopenia (23%) and anemia (15%) were more common and frequently dose limiting. The combined partial and complete response rate was found to be 84%, with a median follow up of only three months in patients not previously receiving chemotherapy, and was equivalent to the early response rate to oral cyclophosphamide alone in the prior CALGB trial. Despite the higher incidence of leukopenia in previously untreated patients, the combination of oral cyclophosphamide and subcutaneous interferon alfa-2b appears warranted to test the hypothesis that interferon may prevent the conversion to higher grade histology, or improve survival in previously untreated patients with nodular NHL.
This is a preview of subscription content, log in via an institution to check access.
References
Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg SA. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Eng J Med 229:1449, 1978
Gutterman I, Yap Y, Buzdar A, Alexanian R, Hersh E, Cabanillas F, Greenberg S. Leukocyte interferon (IF) induced tumor regression in patients (PTS) with breast cancer and B cell neoplasms. Proc Am Assoc Cancer Res 20:176, 1979
Gutterman IU, Blumesnshein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyl GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignantlymphoma. Ann Intern Med 93:399, 1980
Leavitt RD, Duffey PL, Wiernik PH. A phase I trial of twice daily recombinant human leukocyte α-interferon (IFL-rA) in cancer patients. Proc Am Soc Clin Oncol 1:41, 1982
Sherwin S, Knost J, Fein S, Abrams P, Foon K, Ochs J, Schoenberger C, Oldham R. A multiple dose phase I trial of recombinant leukocyte A interferon using a 3 × weekly schedule. Proc Am Soc Clin Oncol 1:35, 1982
Quesada JR, Gutterman JU, Fein S. A phase I study of recombinant DNA produced leukocyte interferon by an intermittent schedule. Am Soc Clin Oncol, Annual Meeting, April 26–28, St. Louis, MO, 1982
Horning SJ, Levine JF, Miller RA, Merigan TC. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. Second Annual International Congress for Interferon Research, Oct. 21–23, San Francisco, CA, 1981
The non-Hodgkin's lymphoma classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112–2135, 1982
Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J, Jaffe ES, Oldham RK. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Eng J Med 311:1148–1152, 1984
Leavitt RD, Kaplan RS, Bonnern E, Grimm M, Ozer H,Portlock C, Ratanatharathorn V, Ultman J, Rudnick S.High and low dose α-2 interferon treatment for non-Hodgkin's lymphoma. 1st Int Lymphoma Congress, Lugano, Switzerland, June 1984
Peterson BD, Frizzera G, Anderson JR, Bloomfield CD, Pajak TF, Gottlieb AJ, Holland JF. Response of low grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, Adriamycin, vincristine, prednisone and bleomycin(CAVPB). Proc Am Soc Clin Oncol 4:211, 1985
Urba WJ, Longo DL. Cytologic, immunologic, and clinical diversity in non-Hodgkin's lymphoma: Therapeutic implications. Semin Oncol 12:250–267, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ozer, H., Anderson, J.R., Peterson, B.A. et al. Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma. Invest New Drugs 5 (Suppl 4), S27–S33 (1987). https://doi.org/10.1007/BF00207260
Issue Date:
DOI: https://doi.org/10.1007/BF00207260